ACR Appropriateness Criteria® Radiologic Management of Portal Hypertension.

Cirrhosis is a heterogeneous disease that cannot be studied as a single entity and is classified in two main prognostic stages: compensated and decompensated cirrhosis. Portal hypertension, characterized by a pathological increase of the portal pressure and by the formation of portal-systemic collaterals that bypass the liver, is the initial and main consequence of cirrhosis and is responsible for the majority of its complications. A myriad of treatment options exists for appropriately managing the most common complications of portal hypertension, including acute variceal bleeding and refractory ascites. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

• Publication year

  2021

• Venue

  Journal of the American College of Radiology

• Publication date

  2021-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacr.2021.02.013PMID 33958110
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ACR Appropriateness Criteria® Radiologic Management of Gastric Varices.

  2020cited by this paper
• Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome.

  2019cited by this paper
• Model for end-stage liver disease score and hemodynamic instability as a predictor of poor outcome in early transjugular intrahepatic portosystemic shunt treatment for acute variceal hemorrhage

  2018cited by this paper
• The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis

  2018cited by this paper
• Hepatorenal syndrome: the clinical impact of vasoactive therapy

  2018cited by this paper
• Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding

  2018cited by this paper
• Systematic review with meta‐analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1

  2017cited by this paper
• Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials

  2017cited by this paper
• Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT‐0401 and REVERSE randomised clinical studies

  2017cited by this paper
• ACR Appropriateness Criteria® Chronic Liver Disease.

  2017cited by this paper
• Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta‐analysis of randomized controlled trials

  2016cited by this paper
• Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

  2016cited by this paper
• Decreasing mortality among patients hospitalized with cirrhosis in the United States from 2002 through 2010.

  2015cited by this paper
• Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis

  2015cited by this paper
• Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.

  2015cited by this paper
• Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial

  2015cited by this paper
• Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.

  2015cited by this paper
• The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique

  2015cited by this paper
• Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension

  2015cited by this paper
• MELD score for prediction of survival after emergent TIPS for acute variceal hemorrhage: derivation and validation in a 101-patient cohort.

  2015cited by this paper
• Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs.

  2014cited by this paper
• A MELD-based model to determine risk of mortality among patients with acute variceal bleeding.

  2014cited by this paper
• Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis

  2014cited by this paper
• TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.

  2014cited by this paper
• Salvage transjugular intrahepatic portosystemic shunt followed by early transplantation in patients with Child C14‐15 cirrhosis and refractory variceal bleeding: a strategy improving survival

  2013cited by this paper
• The First Egyptian Experience Using New Self-Expandable Metal Stents in Acute Esophageal Variceal Bleeding: Pilot Study

  2013cited by this paper
• Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012

  2013cited by this paper
• Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.

  2013cited by this paper
• Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study

  2013cited by this paper
• Treatment of Esophageal Variceal Hemorrhage with Self-Expanding Metal Stents as a Rescue Maneuver in a Swiss Multicentric Cohort

  2013cited by this paper
• Percutaneous transhepatic variceal embolization with cyanoacrylate vs. transjugular intrahepatic portal systematic shunt for esophageal variceal bleeding

  2013cited by this paper
• Percutaneous Transsplenic Access to the Portal Vein for Management of Vascular Complication in Patients with Chronic Liver Disease

  2012cited by this paper
• Treatment of portal hypertension.

  2012cited by this paper
• Acute Variceal Bleeding

  2012cited by this paper
• Percutaneous placement and management of the Denver shunt for portal hypertensive ascites.

  2012cited by this paper
• Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial.

  2012cited by this paper
• Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study.

  2012cited by this paper
• Management of ascites in cirrhosis

  2012cited by this paper
• Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.

  2012cited by this paper
• Acute Management of Refractory Variceal Bleeding in Liver Cirrhosis by Self-Expanding Metal Stents

  2012cited by this paper
• Meta‐analysis: vasoactive medications for the management of acute variceal bleeds

  2012cited by this paper
• Meta‐analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding – an updated Cochrane review

  2011cited by this paper
• Accuracy of MELD Scores in Predicting Mortality in Decompensated Cirrhosis from Variceal Bleeding, Hepatorenal Syndrome, Alcoholic Hepatitis, or Acute Liver Failure As Well As Mortality After Non-transplant Surgery or TIPS

  2011cited by this paper
• What's Hot in the Red Journal This Month

  2011cited by this paper
• Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

  2011cited by this paper
• Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity

  2011cited by this paper
• Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding

  2011cited by this paper
• Endoscopic treatment of esophageal varices in advanced liver disease patients: band ligation versus cyanoacrylate injection

  2011cited by this paper
• Hepatorenal syndrome

  2011cited by this paper
• Early use of TIPS in patients with cirrhosis and variceal bleeding.

  2010cited by this paper
• Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial

  2010cited by this paper
• Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis

  2010cited by this paper
• A self-expanding metal stent for complicated variceal hemorrhage: experience at a single center.

  2010cited by this paper
• Portal vein thrombosis and survival in patients with cirrhosis

  2010cited by this paper
• Surgical Shunting versus Transjugular Intrahepatic Portasystemic Shunting for Bleeding Varices Resulting from Portal Hypertension and Cirrhosis: A Meta-Analysis

  2010cited by this paper
• Clinical trial: short‐term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double‐blind, placebo‐controlled study

  2010cited by this paper
• Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites

  2010cited by this paper
• Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.

  2010cited by this paper
• Stent-grafts for transjugular intrahepatic portosystemic shunt creation: specialized TIPS stent-graft versus generic stent-graft/bare stent combination.

  2010cited by this paper
• EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

  2010cited by this paper
• TIPS: comparison of shunt patency and clinical outcomes between bare stents and expanded polytetrafluoroethylene stent-grafts.

  2009cited by this paper
• Management of adult patients with ascites due to cirrhosis: An update

  2009cited by this paper
• Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices

  2009cited by this paper
• Prediction of Mortality after Emergent Transjugular Intrahepatic Portosystemic Shunt Placement: Use of APACHE II, Child-Pugh and MELD Scores in Asian Patients with Refractory Variceal Hemorrhage

  2009cited by this paper
• Renal failure in cirrhosis.

  2009cited by this paper
• An Open Label, Pilot, Randomized Controlled Trial of Noradrenaline Versus Terlipressin in the Treatment of Type 1 Hepatorenal Syndrome and Predictors of Response

  2008cited by this paper
• Prevention of paracentesis‐induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study

  2008cited by this paper
• Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome

  2008cited by this paper
• Results of a new method to stop acute bleeding from esophageal varices: implantation of a self-expanding stent

  2008cited by this paper
• The management of portal hypertension: rational basis, available treatments and future options.

  2008cited by this paper
• Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy.

  2008cited by this paper
• A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

  2008cited by this paper
• Midodrine Versus Albumin in the Prevention of Paracentesis-Induced Circulatory Dysfunction in Cirrhotics: A Randomized Pilot Study

  2008cited by this paper
• Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial

  2008cited by this paper
• Percutaneous transsplenic access in the management of bleeding varices from chronic portal vein thrombosis.

  2007cited by this paper
• The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study.

  2007cited by this paper
• Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

  2007cited by this paper
• Radiological Insertion and Management of Peritoneovenous Shunt

  2007cited by this paper
• Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long‐term results of a randomized multicentre study

  2007cited by this paper
• Natural history of patients hospitalized for management of cirrhotic ascites.

  2006cited by this paper
• Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial.

  2006cited by this paper
• Improved Prognosis of Cirrhosis Patients with Esophageal Varices and Thrombocytopenia Treated by Endoscopic Variceal Ligation Plus Partial Splenic Embolization

  2006cited by this paper
• Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review.

  2006cited by this paper
• Transjugular Intrahepatic Portosystemic Shunt (TIPS), the Preferred Therapeutic Option for Budd Chiari Syndrome Associated with Portal Vein Thrombosis

  2006cited by this paper
• Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation

  2006cited by this paper
• Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.

  2006cited by this paper
• A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding.

  2006cited by this paper
• Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

  2006cited by this paper
• Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:

  2006cited by this paper
• Terlipressin versus albumin in paracentesis‐induced circulatory dysfunction in cirrhosis: A randomized study

  2006cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2005cited by this paper
• Chronic Albumin Infusions to Achieve Diuresis in Patients with Ascites Who Are Not Candidates for Transjugular Intrahepatic Portosystemic Shunt (TIPS)

  2005cited by this paper
• Transjugular Intrahepatic Portosystemic Shunt

  2005cited by this paper
• H-Graft Portacaval Shunts Versus TIPS: Ten-Year Follow-up of a Randomized Trial With Comparison to Predicted Survivals

  2005cited by this paper
• Massive pneumoperitoneum: a late complication of the Denver pleuroperitoneal shunt.

  2005cited by this paper
• MELD Score as a Predictor of Early Death in Patients Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedures

  2005cited by this paper
• Efficacy of absolute alcohol injection compared with band ligation in the eradication of esophageal varices.

  2005cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2005cited by this paper
• Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome

  2004cited by this paper
• LIVER FAILURE AND LIVER DISEASE

  2004cited by this paper

• Percutaneous Transhepatic Variceal Embolization as a Therapeutic Bridge for Variceal Bleeding: An Initial Alternative in the Absence of Endoscopy or Transjugular Intrahepatic Portosystemic Shunt (TIPS).

  2026cites this paper
• Chronic Portal Vein Thrombosis: Diagnosis, Management, and Review of the Literature.

  2025cites this paper
• TIPS Revision: Indications, Techniques, and What to Consider When Revision Fails.

  2025cites this paper
• Refractory ileocolic variceal bleeding in hemorrhagic shock: Endoscopy-negative stigmata, failed TIPS, and successful control with targeted embolization of an ectopic varix

  2025cites this paper
• Evidences and perspectives of transjugular intrahepatic portosystemic shunt: A bibliometric analysis from 1990 to 2024

  2025cites this paper
• Proposed Clinical Practice Guidance for Large-Volume Abdominal and Pleural Paracentesis with Emphasis on Coagulopathy Management

  2025cites this paper
• ACR Appropriateness Criteria® Nonvariceal Upper Gastrointestinal Bleeding: 2024 Update.

  2024cites this paper
• Paradoxical Cerebral Embolization during Transjugular Intrahepatic Portosystemic Shunt Creation and Variceal Sclerotherapy

  2024cites this paper
• Prediction of mortality and overt hepatic encephalopathy undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study

  2023cites this paper
• LVP vs TIPS for Refractory Ascites: Where Do We Stand?

  2022cites this paper
• Transjugular Intrahepatic Portosystemic Shunt

  2022cites this paper
• Expanding Indications of TIPS in the Management of Portal Hypertension Complications

  2022cites this paper
• Expert Panels on Vascular and Gastrointestinal Imaging

  year unknowncites this paper